| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.063 | 0.06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.06 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.06 |